On January 24, 2020, the FDA is scheduled to announce its decision on two of Merck’s (MRK) applications for Dificid, which are under priority review.The applications under review include a New Drug Application for Dificid oral suspension for the treatment of Clostridium difficile infections and a supplemental NDA for Dificid tablets and oral suspension for the treatment of pediatric patients aged 6 months or older.Currently, Dificid, a macrolide antibacterial drug, is available only in a tablet formulation for adults (18 years of age or older) for treatment of Clostridium difficile-associated diarrhea.MRK closed Monday’s (Dec.30, 2019) trading at $91.03, down 0.51%.